针对潜在产AmpC酶菌株的β-内酰胺类/β-内酰胺酶抑制剂治疗：一项系统评价和荟萃分析
Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis.
作者信息
Cheng Matthew P, Lee Robyn S, Cheng Alexandre P, De L'étoile-Morel Samuel, Demir Koray, Yansouni Cedric P, Harris Patrick, Mcdonald Emily G, Lee Todd C
机构信息
Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
出版信息
Open Forum Infect Dis. 2019 Jul 1;6(7). doi: 10.1093/ofid/ofz248.
The optimal treatment for potential AmpC-producing Enterobacteriaceae, including Serratia, Providencia, Citrobacter, Enterobacter, and Morganella species, remains unknown. An updated systematic review and meta-analysis of studies comparing beta-lactam/beta-lactamase inhibitors with carbapenems in the treatment of bloodstream infections with these pathogens found no significant difference in 30-day mortality (OR, 1.13; 95% CI, 0.58 - 2.20).
对于可能产AmpC酶的肠杆菌科细菌，包括沙雷菌属、普罗威登斯菌属、柠檬酸杆菌属、肠杆菌属和摩根菌属，其最佳治疗方法尚不清楚。一项最新的系统评价和荟萃分析比较了β-内酰胺/β-内酰胺酶抑制剂与碳青霉烯类药物治疗这些病原体所致血流感染的效果，结果发现30天死亡率无显著差异（比值比，1.13；95%置信区间，0.58 - 2.20）。
Zotero 插件